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Background: Whilst still rare, the incidence of paediatric stone disease is increasing in developed countries and it is
important to evaluate the aetiology. We set up a dedicated renal stone service for children combining medical and
surgical expertise in 1993 and now have a large case series of children to investigate the epidemiology.
Methods: A retrospective hospital note review of children presenting with kidney stones during the last 22 years
(1993–2015) was conducted. All patients had a comprehensive infective and metabolic screen and were classified
as metabolic, infective or idiopathic stone disease.
Results: Five hundred eleven patients (322 male) were reviewed. The median age of presentation was 4.4y for
males (1 m-16.6y) and 7.3y (1–18.5y) for females with a median height and weight on the 25th centile for male and
on 10th and 25th for female, respectively. One hundred seventy five (34%) had an underlying metabolic
abnormality, 112 (22%) had infective stones and 224 (44%) were classified as idiopathic.
Of the 175 patients with a metabolic abnormality: 91 (52%) had hypercalciuria (76 persistent and 15 transient),
37 (21%) hyperoxaluria, 38 (22%) cystinuria, 3 (2%) abnormalities in the purine metabolism and the remainder
other metabolic abnormalities. Bilateral stones occurred in 27% of the metabolic group compared to 16% in
the non-metabolic group (OR 0.2, p < 0.05). Urinary tract infection was a common complication (27%) in the
metabolic group.
Conclusions: In this paper, we present the largest cohort of paediatric stone disease reported from a developed
country giving details on both, clinical and laboratory data. We show that in the majority of the patients there is
an identifiable underlying metabolic and/or infective aetiology emphasizing the importance of a full work up to
provide adequate treatment and prevent recurrence. Moreover, we show that stone disease in children, in
contrast to the adult population, does not seem to be associated with obesity, as children have a weight below
average at presentation.
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Whilst still rare, the incidence of paediatric stone disease is
increasing in developed countries and is associated with
significant morbidity [1–3]. It is especially important in
children to understand the epidemiology of stone disease
in order to provide adequate treatment and to develop pre-
ventive strategies. However, like many paediatric disorders,
data on children with stone disease are rare compared to
the adult population. In the last British epidemiological
study of paediatric nephrolithiasis, in 2003 [4], our group
concluded that 44% of stones were principally secondary to
a metabolic abnormality, 30% were classified as infective
and the rest categorise as idiopathic. Fifty percent of stone
composition was calcium-phosphate or calcium oxalate.
To examine if these findings are still relevant one decade
later, we have repeated this review in stone disease in our
centre over the past 22 years.
Methods
We performed a retrospective note review of radiological
and metabolic data for all children presenting during the
period from November 1993 to August 2015, including
patients previously reported in 2003 by Coward et al.
[4]. Since 1993, all children presenting with a renal stone
to Great Ormond Street Hospital NHS Foundation
Trust (GOSH) receive a comprehensive metabolic evalu-
ation. For retrospective analysis of anonymised patient
data no specific ethical approval is needed in our Trust.
All children were reviewed by a consultant paediatric
nephrologist (WVH) in a dedicated, multidisciplinary
paediatric renal stone clinic using a specific list of ques-
tions and a standard metabolic screen. All children were
screened with plasma levels of urea, creatinine, serum
electrolytes, including calcium, phosphorus, magnesium,
bicarbonate, alkaline phosphatase, albumin, urate, vita-
min D and PTH. As our clinic is hold in the morning
and patients usually had breakfast before they travelled
to the hospital, samples used for blood and urine
analysis were mostly non-fasted samples. Their mid-
morning urine was analysed for infection by formal
microscopy and culture, and sent for determination of
calcium, urate, oxalate, cystine and creatinine (by stand-
ard laboratory methods). Urinary citrate was not mea-
sured routinely but only at the discretion of the treating
physician based on clinical indication.
Where possible, 24-h urine collection was performed.
Stones were analysed in a recognised laboratory for
chemical composition by IR-spectroscopy.
Medical treatment was obtained retrospectively from
the hospital notes. Initially, 543 attenders to the stone
clinic were identified in the 22-year period, of which 32
were omitted due to inadequate patient details or having
no evidence of stone according to expert radiologist
interpretation of the referral patient status.Patients were classified as having a metabolic predis-
position for stone formation according to the following
criteria [5]:
Hypercalciuria
Was defined as a non-fasting, spot urinary calcium: creatin-
ine (Ca:Cr) ratio above the age specific Western society
reference values (Birth-1 year up-to 2.2 mmol/mmol; 1–2
years 1.5 mmol/mmol; 2–3 years 1.4 mmol/mmol; 3–5
years 1.1 mmol/mmol; 5–7 years 0.8 mmol/mmol; 7–17
years 0.7 mmol/mmol) [6]. If the child was old enough to
cooperate, a 24 h urine was collected (Adequate collection
was estimated via measuring 24 h creatinine of 0.1–
0.2 mmol/kg/day); hypercalciuria was diagnosed if the
calcium excretion was 0.1 mmol/kg/day or above [7]. Mini-
mum of two abnormal results were considered as hypercal-
ciuria. A child who had a raised Ca:Cr ratio that returned
to normal after stone removal was defined as transient
hypercalciuria. Children with persistent hypercalciuria who
were forming stones despite increasing fluid intake and low
salt diet, were treated with Thiazide diuretic.
Hyperoxaluria
Was defined as a non-fasting, spot urinary oxalate: cre-
atinine (Ox:Cr) ratio above the age specific Western
society reference values (Birth-1 year up-to 98 μmol/
mmol; 1–4 years 72 μmol/mmol; 5–12 years 71 μmol/
mmol; above 12 years 38 μmol/mmol) [6]. Abnormalities
were confirmed by another spot Ox:Cr ratio or if pos-
sible, by a 24 h urine collection into an acidified con-
tainer [8]. Normal values considered as 100–460 μmol/
day/1.73 m2 of oxalate excretion. (Adequate collection
was estimated via measuring 24 h creatinine of 0.1–
0.2 mmol/kg/day) [9]. In cases of persistent hyperoxa-
luria, urine was also sent for glycolate: creatinine ratio as
well as measurement of L-glycerate. Genetic analysis
confirmed the diagnosis for primary hyperoxaluria type
1, type 2 or type 3 (AGXT, GRHPR, HOGA1 respect-
ively) [10, 11]. Enteric hyperoxaluria was defined as
secondary hyperoxaluria related to congenital gut abnor-
mality, bowel resection or chronic diarrhoea. Patients
with primary hyperoxaluria type 1 (PH-1) received a
treatment trial of Pyridoxine.
Cystinuria
Was defined as cystine levels above 20 μmol/mmol
creatinine. Other dibasic amino acids (ornithine, lysine,
and arginine) were measured to support diagnosis
(defined by semi quantitative methods or quantitative
urinary amino acid determination by ion exchange chro-
matography). Children with proven Cystinuria who were
forming stones despite increasing fluid intake and
alkalinizing urine, were treated with D-penicillamine or
Tiopronin.
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Was defined as repeated increased spot urines of urate:
Creatininine level greater than age specific reference
values (birth-7 days up-to 1.96 mmol/mmol; 7 days to
2 years 1.53 mmol/mmol; 2–6 years 1.35 mmol/mmol;
6–10 years 0.85 mmol/mmol: 10–18 years 0.67 mmol/
mmol) [6]. These were then confirmed with 24 h collec-
tions against age specific reference (adequate collection
was estimated via measuring 24 h creatinine of 0.1–
0.2 mmol/kg/day) [12]. Patients with other purine-
containing stones were assessed with more specific
metabolic investigations.Hypocitraturia
Was defined as citrate levels below 0.11–0.55 mmol/
mmol creatinine for females and 0.04–0.33 mmol/mmol
creatinine for males.
Patients were classified as having an infective or idio-
pathic stone formation according to the following criteria:
Infective. Was defined as the presence of urinary tract
infection (UTI) or past medical history of UTI, in the
absence of metabolic abnormalities.
Idiopathic. Was defined as the absence of infective and
metabolic abnormalities.Statistics
Data were analysed for normality using the Kolmogorov-
Smirnov test. Non-normal or skewed data are presented
in median and range and non parametric tests (or
methods) were used for analysis. Significance was
assessed by Mann-Whitney U Test for non-parametric
data and Chi-Square Test for categorical variables. We
used IBM SPSS Statistics Version 23 for Mac.Age at presentation (years)
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aetiology and stratified by sexResults
Incidence, age, and sex at presentation
Five hundred and eleven patients (322 boys and 189
girls; 1.7:1 boys: girls), were included over the 22-year
period. The median age of presentation was 4.4 years for
males (range 1 months - 16.6 years) and 7.25 years
(range 1 months - 18.5 years) for females (Fig. 1).
Presenting features
Most children presented with one or more classic symp-
toms of stone disease (pain, haematuria, UTI) but the
frequency of symptoms was variable (Table 1). Of the
total group, only 163 (32%) had a history of abdominal
pain, with a lower frequency in children < 6 years, 183
(36%) had UTI, 137 (27%) macroscopic haematuria, and
64 (13%) had painful haematuria (defined as abdominal
pain in combination with macroscopic haematuria). In
contrast, 67 (13%) patients were asymptomatic and the
stone was discovered coincidentally (n = 58) or due to
positive family history screening (n = 9). Seven (1.4%)
presented with features of acute kidney injury.
Data on family history were available in 279 patients. Out
of those, 85 (30%) had a family history positive for renal
stone diseases: first degree relatives in 11%, second degree
relatives in 10% and more than 1 relative affected in 9%.
Fifty (10%) children were born prematurely with a
median gestational age of 29 (range 24 – 36) weeks.
Those children presented significantly younger than the
rest of the population at a median age of 2.4 years (range
1 months – 13.3 years) (p < 0.05). There was no differ-
ence in the stone composition or the family history com-
pared to the rest of the population.
Out of the whole population 25 (5%) had a history of
prolonged immobility (mainly wheel-chair bound) sec-
ondary to various neurological impairment.Aetiology
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Table 1 Presenting features of all patients
Presenting features
(n = 522)
Number of patients
(%)
Missing data
(%)
Symptoms 522 (100%) 0
Abdominal pain 163 (32%)
UTI 183 (36%)
Macroscopic haematuria 137 (27%)
Painful haematuria 64 (13%)
Asymptomatic 67 (13%)
Coincidental finding 58 (11%)
Screening 9 (1.8%)
Acute kidney injury 7 (1.4%)
Family history 279 (55%) 232 (45%)
positive for stone disease 85 (30%)
1st degree 31 (11%)
2nd degree 28 (10%)
more than 1 relative 26 (9%)
Premature birth 50 (10%) 0
Immobility 25 (5%) 0
Renal structural abnormalities 93 (18%) 0
Height data 214 (42%) 297 (58%)
Height centile male 25th (0.4–99)
Height centile female (see Fig. 2) 10th (0.4–91)
Weight data 209 (41%) 302 (59%)
Weight centile male 25th (0.4–99)
Weight centile female (see Fig. 2) 25th (0.4–91)
Features at presentation including the number of missing data where
appropriate. Nominal data are presented in n and %; Growth data are
presented in median and range
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normalities such as: hydronephrosis, pelvic–ureteric
junction stenosis, ureteric-vesico junction stenosis and
or cyst. Of those 93 patients, 30 (32%) were defined as
metabolic, 21 (23%) infective, and 42 (45%) were idio-
pathic stone formers.
Growth data at presentation were available for 214 pa-
tients and weight for 209 patients. For the male group
the median centile for height was 25th (range 0.4–99)
and for weight 25th (range 0.4–99) and for the female
group 10th (range 0.4–91) and 25th (range 0.4–91),
respectively (Fig. 2). The median centile for BMI at pres-
entation was the 50th (range 3–97) for boys and also the
50th (range 3–95) for girls.
Aetiology
One hundred and seventy-five (34%) had an underlying
metabolic abnormality identified, 112 (22%) were classi-
fied as having infective stones and in 224 (44%) we could
not identify an aetiological factor. Infective stones were
more common among children under 6 years of age,with 70% presenting in this period, whereas metabolic
stone formers presented throughout entire childhood.
Metabolic aetiologies
Of the 175 patients with a metabolic abnormality: 91 (52%)
had hypercalciuria (persistent or transient), 37 (21%) hyper-
oxaluria and 38 (22%) cystinuria. Three patients (2%) had
abnormalities in the purine metabolism (autosomal reces-
sive adenine phosphoribosyl transferase deficiency), 3
patients (2%) had hypercalcemia and 1 patient had hyper-
uricosuria. In only approximately 10% of the patients urin-
ary citrate was measured, out of which 2 patients had
documented hypocitraturia. In the metabolic group 62%
were male and the median age of presentation was 5.2 years
(range 1 months - 18.5 years) (Fig. 1b). More than a quarter
(27%) presented with UTI. Within the 76 patients with per-
sistent hypercalciuria, three (4%) had a diagnosis of Familial
hypomagnesaemia with hypercalciuria and nephrocalcinosis
[13], one of them previously published [14]. Immobility and
prematurity contributed to 16 cases. The remainder had
idiopathic hypercalciuria, with no other obvious exacerbat-
ing factors such as special diet or medications. In 44
patients from this group we were able to document their
family history. Interesting, nearly 40% had positive family
history for renal stone. Forty two percent of children having
persistent hypercalciuria were treated with Thiazide diuretic
(along with strict recommendation to limit dietary sodium
intake) trying to increase proximal tubule calcium
reabsorption [15].
The hyperoxaluria group included 19 (51.4%) patients
with primary hyperoxaluria: twelve with type 1, two with
type 2 and five with type 3. In eleven children (29.7%)
we could not identify a mutation in one of the known
genes and therefore they were categorised as non-type
1–3. The remaining seven patients had enteral hyperox-
aluria. Nine patients with PH-1 were treated with Pyri-
doxine which may stabilise the defective alanine
glyoxylate aminotransferase (AGT) enzyme or may act
as a chaperone to restore a low level of normal AGT
activity [16].
Autosomal recessive Adenine phosphoribosyl transfer-
ase deficiency (APRT) was found in 3 patients after
stone analysis showed 2, 8-dihydroxadenine [17]. Two
presented with UTI and one with abdominal pain and
microscopic haematuria.
Infective stones
These occurred in 112 patients, median age of presenta-
tion was 4.0 years (range 2 months - 13.8 years) (Fig. 1b),
the majority were male (68%) and boys were significantly
younger at presentation than girls (42.5 vs 65 months, p
= 0.001). A third (35%) had staghorn stones resulting in
acute kidney injury at presentation in one patient. Ten
children (9%) were found to have chronic kidney disease
Table 2 Stone composition and corresponding aetiologies
Stone composition (n = 300) Metabolic Infective Idiopathic
Calcium oxalate 44 (14.7%) 8 (2.6%) 50 (16.6%)
Calcium phosphate 42 (14%) 49 (16.3%) 42 (14%)
Triple phosphate 2 (0.7%) 32 (10.7%) 6 (2%)
Cystine 20 (6.7%) 0 0
Uric Acid 0 1 (0.3%) 4 (1.3%)
Fig. 2 Boxplot of height and weight centile for male and female patients at presentation
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compared to 9 (4%) in the idiopathic group and 16 (9%)
in the metabolic group. Children with infective stones
presented at a significantly younger age compared to the
metabolic group (4 years (range 2 months to 13.8 years)
versus 5.2 years (range 1 month to 18.5 years); p =
0.016). The male:female ratio was 2.1:1, compared to the
metabolic group of 1.6:1 (p = 0.336).
Stone distribution
The stone was in the upper tract in 413 children (81%),
unilateral on the left in 180 (44%), on the right in 134
(32%), and bilateral in 99 (24%). In 26 (5%) cases the
stones were located in the bladder and upper tract.
Metabolic abnormality was found in 47% of children
with bilateral stone. The risk of presenting with bilateral
stones was increased significantly in children with an
underlying metabolic abnormality, with 47 of 175 (27%)
having bilateral stones in the metabolic group compared
to 52 of 336 (16%) in the non-metabolic group (Odds
ratio 2.0; p = 0.002). Lower distribution of stone, e.g.,:
ureter, bladder or urethra was significantly lower (30%)
compared to the presence of stone within the kidney
parenchyma or the intrarenal collecting system.
Stone composition
Stone analysis was available in 300 patients (58%). The
majority of stone analysed were composed of calcium
oxalate or calcium phosphate (78%). Triple phosphate
stones were detected in 14%, and cystine stone in 7%.
See Table 2.
In 211 cases, stone composition could not be evalu-
ated due to spontaneously passage of gravel or post
lithotripsy procedure.
Sub analysis -comparison 1993–2001 and 2002–2015
In sub-analysis we compared findings of 133 patients
from 1993 to 2001, of which 106 were represented also
in our first audit [4] with the 378 patients in the morerecent era (2002–2015). There was no significant differ-
ence in gender, age of presentation and aetiology.
Discussion
We here present the largest cohort of paediatric stone
disease giving details on both, clinical and laboratory
data, in western developed countries reported to date
[1, 2, 18–25]. This unique study provides data regarding
the epidemiology and laboratory characteristics of 511
paediatric kidney stone formers and assessed the aetiology
of nephrolithiasis within this distinctive group.
The only paediatric study involving more children al-
though provided only data on microscopic examination and
infrared spectroscopy of calculi and no clinical data [26].
The well-documented male preponderance, espe-
cially in the younger age group, has again been con-
firmed [19, 20, 27], although a few paediatric series
have shown female predominance [22, 28]. Most epi-
demiologic studies of symptomatic urolithiasis in
adults also show a male preponderance [29, 30].
Most paediatric series note a significant number of
adolescents with stones, and an increase in stones in
patients in this age group over time [1, 3]. Yet in our
series there were few patients who presented after
13 years of age, which may reflect a referral bias in our
population. It is possible, that older children may be
referred to an adult nephrologist or urologist.
Presentation of nephrolithiasis in children is frequently
atypical [19], which may explain why only 32% were per-
ceived to have pain and 13% to have had painful macro-
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the classic signs and symptoms of urolithiasis, such as flank
or abdominal pain and gross haematuria [31]. This symp-
tom may go unrecognised in younger paediatric patients,
who may find it difficult to localise or describe their symp-
toms. Urinary tract infection was the presenting symptom
in more than a quarter of patients who were subsequently
noted as having an underlying metabolic abnormality. This
indicates the importance of metabolic evaluation in every
child presenting with urinary tract infection and stone
disease, primarily to initiate a preventive therapy.
In the adult population obesity has been found to be a
risk factor for kidney stone formation [32–34]. Similar
findings have been reported in an American study of
mainly adolescent stone formers (average age 12 years),
where 31% of the children were considered obese [19].
That is in contrast to our findings, where we observed
that the median centile of weight for male and female
stone formers was below the 50th centile for a healthy
population. Moreover, the height was also below the
50th centile for a healthy population, demonstrating that
paediatric stone formers are more likely to suffer from
failure to thrive or that co-morbidity contributed to
growth delay. Dwyer et al. [3] and Sas D.J. [2] reported
similar findings, stating that obesity is not a contributing
factor to the increasing incidence of kidney stones in
paediatric stone formers and in fact they have a lower
BMI on average than general paediatric population.
The aetiology of paediatric urolithiasis is influenced by
the scope of the metabolic work-up, the accepted defin-
ition and by the geographic area. The aim of conducting
a metabolic and infective evaluation is to be able to im-
plement an appropriate treatment which may minimise
the risk of recurrent stones. More than half (56%) of our
patients were found to have metabolic or infective
stones, which also prevail in most series throughout the
world [1, 20, 22, 28]. Hypercalciuria is the most common
metabolic cause of paediatric urolithiasis [35]. It was
noted in 43% of our patients with metabolic urolithiasis
(15% among the whole cohort). Other groups have
found hypercalciuria among patients with urolithiasis to
vary from 7 to 34% [20, 22, 28, 36]. Of 37 children with
hyperoxaluria, 19 (51%) had primary hereditary variant.
The high proportion of such patients in our series reflects
the tertiary referral nature of the practice at GOSH. Hypo-
citraturia is in other studies reported with an incidence up
to 15–50% [2, 19]. In our population urinary citrate was
unfortunately only measured in selected cases, the deci-
sion residing with the treating clinician. Therefore, we
cannot draw any epidemiological conclusions regarding
the role of hypocitraturia in our cohort.
Infectious stones were found in 22% of patients, 70%
were younger than 6 years at presentation. In the vast
majority of the infected stone Proteus was isolated. Thisis consistent with struvite (i.e., ammonium-magnesium
phosphate or triple phosphate) urolithiasis occuring in
the presence of infection by urease producing microor-
ganisms. In our cohort 32 (29%) of children with infect-
ive stone had pure triple phosphate stone, while the rest
had calcium-phosphate or calcium-oxalate stone com-
position. Nearly ten percent from the infective group
ended up with some degree of chronic kidney disease
(CKD). However, out of all children who ended up with
a degree of chronic kidney disease (n = 35), 26% had an
underlying structural abnormality, the likely main con-
tributor to the development of infection and CKD in
paediatric stone formers. Other groups have reported
the increased risk of CKD with nephrolithiasis among
children and adults, especially in the situation of recur-
rent urinary tract infections [24, 28, 37]. Further studies
are needed to better define and characterise infective
stone associated CKD and the patients at increased risk
for this complication.
Within idiopathic stone formers 42 (19%) were found
to have primary renal structural abnormalities, which
may promote urine stasis and increase the risk of
calculus formation without any other underlying disease
[38, 39]. Thirty-eight (17%) of idiopathic stone formers
were born premature and/or had a history of prolonged
immobilisation, which can both provide a known risk
factor for nephrolithiasis [40, 41].
In our population we could not observe a change in
aetiologies over time (1993–2001 vs 2002–2015). Com-
paring our results to the previous published paper by
Coward et al. it appears that the proportion of idiopathic
stone formers is increasing with less metabolic and in-
fective aetiology [4]. However, the main reason for this
discrepancy is, that in our study more rigorous criteria
for classification of a metabolic and infective aetiology
were applied. In order to be classified as metabolic ab-
normal urinary results had to be documented at least
twice. Further, to be classified as infective aetiology, a
positive urine culture had to be available in our labora-
tory. Applying these criteria, both to the initial cohort
(1993–2001) and the subsequent cohort (2002–2015) we
do not see any significant difference (data not shown).
The stone composition is critical for introducing tar-
geted therapy after urinalyses is completed. Like most
stone-forming children, our population demonstrates
predominantly calcium oxalate and calcium phosphate
stones [20, 22, 28, 36]. Comparable to Milliners’ group
[22], magnesium ammonium phosphate stones were
most often noted in the under 6 years age-group.
Interestingly, bilateral stone disease seems to pre-
dict having a metabolic abnormality (48% of our
cases). It may also predict a more severe stone
disease which demands targeted medical and inter-
vention treatment.
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spective audit, resulting in an absence of uniform data
sets. Therefore, we are not able to provide data on crys-
talluria and morphologic analysis which has been shown
to be of interest for the etiologic diagnosis of stone dis-
ease without available stone. Secondary, urinary citrate
was not measured routinely but only at the discretion of
the treating physician. Therefore, our study is not able
to reflect the true number of patients with hypocitraturia
and we cannot draw epidemiological conclusions regard-
ing this metabolic disorder. Also, comprehensive genetic
studies will be needed to define how many patients have
a genetic cause of their kidney stone disease.
Furthermore, our results are based on data obtained from
patients seen in our clinic and not from a population-based
study. Therefore, our results might vary from the overall
paediatric stone disease population in the UK.
Conclusion
In conclusion, we here present the largest cohort of
paediatric stone disease in western developed countries
published up to date demonstrating that metabolic risk
factors accounting for one-third of all calculi with an in-
creased risk of bilateral disease. In contrast to the adult
population, obesity is not a risk factor for stone develop-
ment in the paediatric population.
Future work: Nearly 30% of our children had a positive
family history for stone disease, which may indicate a
genetic component to urolithiasis [42]. Milliner and his
group [22] found even higher numbers particularly
among the hypercalciuric subgroup. At present we do
not know how many patients have a likely genetic cause
of their kidney stone disease. Establishing comprehen-
sive genetic testing for known disease genes is one of
our current priorities. We also believe that conducting a
genome-wide association study (GWAS) might reveal
unknown hereditary traits linked to this phenotype.
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